Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.38 |
| ▸ | KDM1A | O60341 | 4/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.32 |
| ▸ | SAT1 | P21673 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25915063 | 0.98 | CYP2C19 (0.40) | CYP2C19CYP1A2PAOXKDM1ABCHE | |
| SCHEMBL24608228 | 0.93 | CYP2C19 (0.38) | CYP2C19CYP1A2PAOXKDM1AHDAC6 | |
| SCHEMBL25509805 | 0.85 | CHRNB2 (0.32) | CYP2C19CYP1A2MEN1GLAKMT2A | |
| SCHEMBL25828428 | 0.84 | SAT1 (0.36) | CYP2C19CYP1A2MEN1GLAKMT2A | |
| SCHEMBL21106871 | 0.83 | PAOX (0.39) | PAOXBCHECHRM2ACHEHDAC6 | |
| SCHEMBL16384281 | 0.82 | KDM4A (0.40) | PAOXBCHECHRM2ACHEHDAC6 | |
| SCHEMBL23568414 | 0.82 | KDM4A (0.40) | PAOXBCHECHRM2ACHEHDAC6 | |
| SCHEMBL23696537 | 0.81 | PAOX (0.37) | PAOXBCHECHRM2ACHEHDAC6 | |
| SCHEMBL23696191 | 0.81 | HDAC6 (0.37) | PAOXBCHECHRM2ACHEHDAC6 | |
| SCHEMBL22305801 | 0.80 | PAOX (0.44) | CYP2C19CYP1A2PAOXKDM1ABCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230144292-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CYP2C19 3990/4885CYP1A2 3570/4885PAOX 1862/4885 |
| US-20230144292-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CYP2C19 3990/4885CYP1A2 3570/4885PAOX 1862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.